Co-Founder of Clemson University spinoff talks about company’s capabilities in predicting chemotherapy success

Written by   in 

Cancer is the second leading cause of death globally and was responsible for over 9.5 million deaths in 2018, as reported by the American Cancer Society. With over 17 million new cases in the past year, this disease can ravage an apparently healthy person within a matter of months. The effects of treatment methods, such as radiation and chemotherapy, can be an entirely separate, yet equally grueling battle for cancer patients.

KIYATEC, a Clemson University biotech spinoff founded in 2005 by Matthew Gevaert and David Orr, is currently developing innovative techniques that will assist healthcare providers in determining which chemotherapy drugs will be the most effective on individual ovarian cancer patients, using KIYATEC’s Ex Vivo 3D Cell Culture technology (EV3D). 

EV3D, a technology that grew out of research conducted at Clemson University, is a novel method that allows scientists to insert a patient’s cancer cells into a three-dimensional cell culture, an environment that more closely resembles the human body, rather than a traditional, flat petri dish. Using these cell cultures, researchers are able to determine which chemotherapy drugs are the most effective on a person-by-person basis with 89% accuracy rate. 

Based in Greenville, SC, KIYATEC tirelessly works to create a better future for cancer patients. Their research and accomplishments have allowed KIYATEC to make a significant impact on the world of health care. 

To learn more about KIYATEC, click here.

About KIYATEC, Inc.

KIYATEC leverages its proprietary ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors. The company’s Drug Development Services business works in partnership with leading biopharmaceutical companies to unlock response dynamics for their investigational drug candidates across the majority of solid tumor types. The company’s Clinical Services business is currently engaged in the validation of clinical assays as well as investigator-initiated studies in ovarian cancer, breast cancer, glioblastoma and rare tumors, in its CLIA-certified laboratory. To learn more about KIYATEC, visit www.kiyatec.com

KIYATEC receives additional financing for ongoing clinical studies

Written by   in 

KIYATEC, Inc., a South Carolina startup based on technology developed at Clemson University, has recently announced the $3 million initial closing of the company’s B2 financing round. In addition to the funding, KIYATEC has welcomed LabCorp as a new investor. LabCorp’s investment in KIYATEC is of particular significance because of their expertise in oncology and their preclinical and clinical development strengths. With these new developments, KIYATEC is poised to sharpen their ongoing clinical study, 3D-PREDICT.

An innovator in cancer treatment, KIYATEC works to change the future of cancer care through predicting how cancer patients respond to drug therapies. In the past few months, KIYATEC has gained significant momentum. They have demonstrated leading capabilities in modeling and prediction response to immune-oncology therapies at the 110th Annual Meeting of the American Association for Cancer Research (AACR). On April 10th, they were one of 20 startups chosen to participate in the 2019 University Innovation & Entrepreneurship Showcase. Most notably, in 2019 KIYATEC has added three clinical sites to its 3D-PREDICT study and expects to add additional sites soon. 

For more information on KIYATEC, click here

Clemson University spin-off, Kiyatec, LLC, participates in Innovation and Entrepreneurship Showcase on Capitol Hill

KIYATEC, Inc., a Clemson-based company, was selected to participate in The University Innovation and Entrepreneurship Showcase that took place on Capitol Hill on April 10. The event, hosted by the Association of Public and Land-grant Universities (APLU) and the Association of American Universities (AAU), recognizes the impact that federally-funded research has on driving entrepreneurship and innovation. 

KIYATEC’S innovative research on 3D cell culture began at Clemson University. Their ex vivo 3D cell culture technology allows accurate modeling and prediction of cancer patient response to drug therapies. KIYATEC’S validated process uses cancer cells taken from patients via surgical or biopsy tissues to create a life-like replication in order to determine what treatments the patient will respond to prior to beginning the treatment.  

Startups for the showcase were chosen based on the level of student engagement in the startup, the strength of the technology the startup produces, and its relationship to research. For more information on KIYATEC, click here